Tag: Treatment-Resistant Depression

Published in JAMA, the phase 2b trial found that a single dose of the psychedelic compound 5-MeO-DMT significantly reduced depressive ...

The Nasdaq-listed psychedelic medicine developer is expanding its workforce, preparing a US sales operation and engaging healthcare providers ahead of ...

Emyria has begun treating its first patients at a new Sydney clinic, extending its Empax mental health services into New ...

Optimi Health has completed production of a new batch of 5mg naturally derived psilocybin capsules, with the same batch set ...

Emyria (ASX: EMD) is preparing to open its first Sydney clinic in September, with the company saying key operational milestones ...

Australian psychedelic biotechnology company Entropy Neurodynamics (ASX: ENP) has secured Human Research Ethics Committee (HREC) approval to begin what it ...

Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early ...

Global pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire psychedelic drug developer AtaiBeckley, in what would become ...

Compass Pathways has reported positive six-month results from its second Phase 3 clinical trial evaluating COMP360 psilocybin treatment for treatment-resistant ...